Evidence map›Paper›PMID 40977375›Full record

ArticleJournal of the American Medical Informatics Association : JAMIA2025

Predicting treatment retention in medication for opioid use disorder: a machine learning approach using NLP and LLM-derived clinical features.

Fateme Nateghi Haredasht, Ivan Lopez, Steven Tate, Pooya Ashtari, Min Min Chan, Deepali Kulkarni, Chwen-Yuen Angie Chen, Maithri Vangala, Kira Griffith, Bryan Bunning and 6 more

Abstract read
In one paragraph

Article in Journal of the American Medical Informatics Association : JAMIA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Fateme Nateghi HaredashtStanford Center for Biomedical Informatics Research, Stanford, CA 94305, United States.
Ivan LopezStanford University School of Medicine, Stanford, CA 94305, United States.ORCID 0000-0003-0246-2180
Steven TateDepartment of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, United States.
Pooya AshtariDepartment of Electrical Engineering (ESAT), STADIUS Center, KU Leuven, 3001 Leuven, Belgium.
Min Min ChanKKT Technologies, Pte. Ltd., 139951, Singapore.
Deepali KulkarniKKT Technologies, Pte. Ltd., 139951, Singapore.
Chwen-Yuen Angie ChenDivision of Primary Care and Population Health, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States.
Maithri VangalaHolmusk Technologies, Inc., NY 10012, United States.
Kira GriffithHolmusk Europe, Ltd., London, United Kingdom.
Bryan BunningDepartment of Biomedical Data Science, Stanford, CA 94305, United States.
Adam S MinerDepartment of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, United States.
Tina Hernandez-BoussardStanford Center for Biomedical Informatics Research, Stanford, CA 94305, United States.ORCID 0000-0001-6553-3455
Keith HumphreysDepartment of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, United States.
Anna LembkeDepartment of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, United States.
L Alexander VanceHolmusk Technologies, Inc., NY 10012, United States.
Jonathan H ChenStanford Center for Biomedical Informatics Research, Stanford, CA 94305, United States.

Funding

Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
American Heart Association-Strategically Focused Research Network on Diversity in Clinical TrialsBetty Moore Foundation #12409Google, Inc.Gordon and Betty Moore Foundation #12409Human-Centered Artificial IntelligenceNational Institute of Allergy and Infectious Diseases 1R01AI17812101National Institute on Drug Abuse Clinical Trials Network UG1DA015815 - CTN-0136NCATS NIH HHS UL1 TR003142NIDA NIH HHS UG1 DA015815NIHNIH HHS UL1TR003142NIH/National Institute of Allergy and Infectious Diseases 1R01AI17812101NIH/National Institute on Drug Abuse Clinical Trials Network CTN-0136NIH/National Institute on Drug Abuse Clinical Trials Network UG1DA015815NIH-NCATS-CTSA UL1TR003142Stanford Artificial Intelligence in Medicine and ImagingStanford Artificial Intelligence in Medicine and Imaging-Human-Centered Artificial Intelligence (AIMI-HAI) Partnership
6 · The paper itself

Abstract

objectiveBuilding upon our previous work on predicting treatment retention in medications for opioid use disorder, we aimed to improve 6-month retention prediction in buprenorphine-naloxone (BUP-NAL) therapy by incorporating features derived from large language models (LLMs) applied to unstructured clinical notes. MATERIALS AND

methodsWe used de-identified electronic health record (EHR) data from Stanford Health Care (STARR) for model development and internal validation, and the NeuroBlu behavioral health database for external validation. Structured features were supplemented with 13 clinical and psychosocial features extracted from free-text notes using the CLinical Entity Augmented Retrieval pipeline, which combines named entity recognition with LLM-based classification to provide contextual interpretation. We trained classification (Logistic Regression, Random Forest, XGBoost) and survival models (CoxPH, Random Survival Forest, Survival XGBoost), evaluated using Receiver Operating Characteristic-Area Under the Curve (ROC-AUC) and C-index.

resultsXGBoost achieved the highest classification performance (ROC-AUC = 0.65). Incorporating LLM-derived features improved model performance across all architectures, with the largest gains observed in simpler models such as Logistic Regression. In time-to-event analysis, Random Survival Forest and Survival XGBoost reached the highest C-index (≈0.65). SHapley Additive exPlanations analysis identified LLM-extracted features like Chronic Pain, Liver Disease, and Major Depression as key predictors. We also developed an interactive web tool for real-time clinical use. DISCUSSION: Features extracted using NLP and LLM-assisted methods improved model accuracy and interpretability, revealing valuable psychosocial risks not captured in structured EHRs.

conclusionCombining structured EHR data with LLM-extracted features moderately improves BUP-NAL retention prediction, enabling personalized risk stratification and advancing AI-driven care for substance use disorders.

Indexed as

Buprenorphine, Naloxone Drug CombinationMachine LearningNarcotic AntagonistsNatural Language ProcessingOpiate Substitution TreatmentOpioid-Related DisordersAdultBuprenorphineElectronic Health RecordsFemaleHumansLogistic ModelsMaleROC CurveBuprenorphineBuprenorphine, Naloxone Drug CombinationNarcotic Antagonistselectronic health recordslarge language modelsmachine learningnatural language processingopioid use disorderpredictive modelingtreatment attrition

Identifiers

PMID40977375
PMCPMC12646374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.